Cellular and humoral immunogenicity against SARS-CoV-2 vaccination or infection is associated with the memory phenotype of T- and B-lymphocytes in adult allogeneic hematopoietic cell transplant recipients.
Allogeneic hematopoietic cell transplantation
Coronavirus disease 2019 (COVID-19)
Memory B cells
Memory T cells
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
Journal
International journal of hematology
ISSN: 1865-3774
Titre abrégé: Int J Hematol
Pays: Japan
ID NLM: 9111627
Informations de publication
Date de publication:
06 Jun 2024
06 Jun 2024
Historique:
received:
06
10
2023
accepted:
22
05
2024
revised:
10
05
2024
medline:
6
6
2024
pubmed:
6
6
2024
entrez:
6
6
2024
Statut:
aheadofprint
Résumé
We conducted a cross-sectional study to evaluate cellular and humoral immunogenicity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination or infection and examine how lymphocyte subpopulations in peripheral blood correlate with cellular and humoral immunogenicity in adult allogeneic hematopoietic cell transplantation (HCT) recipients. The median period from SARS-CoV-2 vaccination or infection to sample collection was 110.5 days (range, 6-345 days). The median SARS-CoV-2 spike-specific antibody level was 1761 binding antibody units (BAU)/ml (range, 0 to > 11,360 BAU/ml). Enzyme-linked immunosorbent spot (ELISpot) assay of T cells stimulated with SARS-CoV-2 spike antigens showed that interferon-gamma (IFN-γ)-, interleukin-2 (IL-2)-, and IFN-γ + IL-2-producing T cells were present in 68.9%, 62.0%, and 56.8% of patients, respectively. The antibody level was significantly correlated with frequency of IL-2-producing T cells (P = 0.001) and IFN-γ + IL-2-producing T cells (P = 0.006) but not IFN-γ-producing T cells (P = 0.970). Absolute counts of CD8+ and CD4+ central memory T cells were higher in both IL-2- and IFN-γ + IL-2-producing cellular responders compared with non-responders. These data suggest that cellular and humoral immunogenicity against SARS-CoV-2 vaccination or infection is associated with the memory phenotype of T cells and B cells in adult allogeneic HCT recipients.
Identifiants
pubmed: 38842630
doi: 10.1007/s12185-024-03802-3
pii: 10.1007/s12185-024-03802-3
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review. JAMA. 2020;324:782–93.
pubmed: 32648899
doi: 10.1001/jama.2020.12839
Hu B, Guo H, Zhou P, Shi ZL. Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol. 2021;19:141–54.
pubmed: 33024307
doi: 10.1038/s41579-020-00459-7
Sahin U, Muik A, Vogler I, Derhovanessian E, Kranz LM, Vormehr M, et al. BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans. Nature. 2021;595:572–7.
pubmed: 34044428
doi: 10.1038/s41586-021-03653-6
El Sahly HM, Baden LR, Essink B, Doblecki-Lewis S, Martin JM, Anderson EJ, et al. Efficacy of the mRNA-1273 SARS-CoV-2 vaccine at completion of blinded phase. N Engl J Med. 2021;385:1774–85.
pubmed: 34551225
doi: 10.1056/NEJMoa2113017
Vijenthira A, Gong IY, Fox TA, Booth S, Cook G, Fattizzo B, et al. Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients. Blood. 2020;136:2881–92.
pubmed: 33113551
pmcid: 7746126
doi: 10.1182/blood.2020008824
Langerbeins P, Hallek M. COVID-19 in patients with hematologic malignancy. Blood. 2022;140:236–52.
pubmed: 35544585
pmcid: 9098396
doi: 10.1182/blood.2021012251
Sharma A, Bhatt NS, St Martin A, Abid MB, Bloomquist J, Chemaly RF, et al. Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study. Lancet Haematol. 2021;8:e185–93.
pubmed: 33482113
pmcid: 7816949
doi: 10.1016/S2352-3026(20)30429-4
Ljungman P, de la Camara R, Mikulska M, Tridello G, Aguado B, Zahrani MA, et al. COVID-19 and stem cell transplantation; results from an EBMT and GETH multicenter prospective survey. Leukemia. 2021;35:2885–94.
pubmed: 34079042
pmcid: 8171362
doi: 10.1038/s41375-021-01302-5
Schaffrath J, Brummer C, Wolff D, Holtick U, Kröger N, Bornhäuser M, et al. High mortality of COVID-19 early after allogeneic stem cell transplantation: a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group. Transplant Cell Ther. 2022;28:337.e1-337.e10.
pubmed: 35296445
doi: 10.1016/j.jtct.2022.03.010
Piechotta V, Mellinghoff SC, Hirsch C, Brinkmann A, Iannizzi C, Kreuzberger N, et al. Effectiveness, immunogenicity, and safety of COVID-19 vaccines for individuals with hematological malignancies: a systematic review. Blood Cancer J. 2022;12:86.
pubmed: 35641489
pmcid: 9152308
doi: 10.1038/s41408-022-00684-8
Sette A, Crotty S. Adaptive immunity to SARS-CoV-2 and COVID-19. Cell. 2021;184:861–80.
pubmed: 33497610
pmcid: 7803150
doi: 10.1016/j.cell.2021.01.007
Kedzierska K, Thomas PG. Count on us: T cells in SARS-CoV-2 infection and vaccination. Cell Rep Med. 2022;3: 100562.
pubmed: 35474748
pmcid: 8872824
doi: 10.1016/j.xcrm.2022.100562
Bertoletti A, Le Bert N, Tan AT. SARS-CoV-2-specific T cells in the changing landscape of the COVID-19 pandemic. Immunity. 2022;55:1764–78.
pubmed: 36049482
pmcid: 9385766
doi: 10.1016/j.immuni.2022.08.008
Almendro-Vázquez P, Laguna-Goya R, Paz-Artal E. Defending against SARS-CoV-2: the T cell perspective. Front Immunol. 2023;14:1107803.
pubmed: 36776863
pmcid: 9911802
doi: 10.3389/fimmu.2023.1107803
Redjoul R, Le Bouter A, Beckerich F, Fourati S, Maury S. Antibody response after second BNT162b2 dose in allogeneic HSCT recipients. Lancet. 2021;398:298–9.
pubmed: 34270933
pmcid: 8277189
doi: 10.1016/S0140-6736(21)01594-4
Maneikis K, Šablauskas K, Ringelevičiūtė U, Vaitekėnaitė V, Čekauskienė R, Kryžauskaitė L, et al. Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study. Lancet Haematol. 2021;8:e583–92.
pubmed: 34224668
pmcid: 8253543
doi: 10.1016/S2352-3026(21)00169-1
Le Bourgeois A, Coste-Burel M, Guillaume T, Peterlin P, Garnier A, Béné MC, et al. Safety and antibody response after 1 and 2 doses of BNT162b2 mRNA vaccine in recipients of allogeneic hematopoietic stem cell transplant. JAMA Netw Open. 2021;4: e2126344.
pubmed: 34519770
pmcid: 8441592
doi: 10.1001/jamanetworkopen.2021.26344
Dhakal B, Abedin S, Fenske T, Chhabra S, Ledeboer N, Hari P, et al. Response to SARS-CoV-2 vaccination in patients after hematopoietic cell transplantation and CAR T-cell therapy. Blood. 2021;138:1278–81.
pubmed: 34339501
pmcid: 8332674
doi: 10.1182/blood.2021012769
Canti L, Humblet-Baron S, Desombere I, Neumann J, Pannus P, Heyndrickx L, et al. Predictors of neutralizing antibody response to BNT162b2 vaccination in allogeneic hematopoietic stem cell transplant recipients. J Hematol Oncol. 2021;14:174.
pubmed: 34689821
pmcid: 8542409
doi: 10.1186/s13045-021-01190-3
Tamari R, Politikos I, Knorr DA, Vardhana SA, Young JC, Marcello LT, et al. Predictors of humoral response to SARS-CoV-2 vaccination after hematopoietic cell transplantation and CAR T-cell therapy. Blood Cancer Discov. 2021;2:577–85.
pubmed: 34778798
pmcid: 8580614
doi: 10.1158/2643-3230.BCD-21-0142
Bergman P, Blennow O, Hansson L, Mielke S, Nowak P, Chen P, et al. Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial. EBioMedicine. 2021;74: 103705.
pubmed: 34861491
pmcid: 8629680
doi: 10.1016/j.ebiom.2021.103705
Mamez AC, Pradier A, Giannotti F, Petitpas A, Urdiola MF, Vu DL, et al. Antibody responses to SARS-CoV2 vaccination in allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant. 2021;56:3094–6.
pubmed: 34584239
pmcid: 8477622
doi: 10.1038/s41409-021-01466-9
Piñana JL, López-Corral L, Martino R, Montoro J, Vazquez L, Pérez A, et al. SARS-CoV-2-reactive antibody detection after SARS-CoV-2 vaccination in hematopoietic stem cell transplant recipients: prospective survey from the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group. Am J Hematol. 2022;97:30–42.
pubmed: 34695229
doi: 10.1002/ajh.26385
Maillard A, Redjoul R, Klemencie M, Labussière Wallet H, Le Bourgeois A, D’Aveni M, et al. Antibody response after 2 and 3 doses of SARS-CoV-2 mRNA vaccine in allogeneic hematopoietic cell transplant recipients. Blood. 2022;139:134–7.
pubmed: 34818411
doi: 10.1182/blood.2021014232
Morsink LM, van Doesum J, Choi G, Hazenberg CLE, Biswana A, Meppelink F, et al. Robust COVID-19 vaccination response after allogeneic stem cell transplantation using post transplantation cyclophosphamide conditioning. Blood Cancer J. 2022;12:6.
pubmed: 35022420
pmcid: 8754065
doi: 10.1038/s41408-021-00605-1
Shem-Tov N, Yerushalmi R, Danylesko I, Litachevsky V, Levy I, Olmer L, et al. Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in haematopoietic stem cell transplantation recipients. Br J Haematol. 2022;196:884–91.
pubmed: 34713441
doi: 10.1111/bjh.17918
Attolico I, Tarantini F, Carluccio P, Schifone CP, Delia M, Gagliardi VP, et al. Serological response following BNT162b2 anti-SARS-CoV-2 mRNA vaccination in haematopoietic stem cell transplantation patients. Br J Haematol. 2022;196:928–31.
pubmed: 34664267
doi: 10.1111/bjh.17873
Yeshurun M, Pasvolsky O, Shargian L, Yahav D, Ben-Zvi H, Rubinstein M, et al. Humoral serological response to the BNT162b2 vaccine after allogeneic haematopoietic cell transplantation. Clin Microbiol Infect. 2022;28:303.e1-303.e4.
pubmed: 34715348
doi: 10.1016/j.cmi.2021.10.007
Tsushima T, Terao T, Narita K, Fukumoto A, Ikeda D, Kamura Y, et al. Antibody response to COVID-19 vaccine in 130 recipients of hematopoietic stem cell transplantation. Int J Hematol. 2022;115:611–5.
pubmed: 35426579
pmcid: 9011370
doi: 10.1007/s12185-022-03325-9
Huang A, Cicin-Sain C, Pasin C, Epp S, Audigé A, Müller NJ, et al. Antibody response to SARS-CoV-2 vaccination in patients following allogeneic hematopoietic cell transplantation. Transplant Cell Ther. 2022;28:214.e1-214.e11.
pubmed: 35092892
doi: 10.1016/j.jtct.2022.01.019
Mori Y, Uchida N, Harada T, Katayama Y, Wake A, Iwasaki H, et al. Predictors of impaired antibody response after SARS-CoV-2 mRNA vaccination in hematopoietic cell transplant recipients: a Japanese multicenter observational study. Am J Hematol. 2023;98:102–11.
pubmed: 36260658
doi: 10.1002/ajh.26769
Toya T, Atsuta Y, Sanada T, Honda T, Sadato D, Sekiya N, et al. Attenuated humoral response against SARS-CoV-2 mRNA vaccination in allogeneic stem cell transplantation recipients. Cancer Sci. 2023;114:586–95.
pubmed: 36161681
doi: 10.1111/cas.15603
Lindemann M, Klisanin V, Thümmler L, Fisenkci N, Tsachakis-Mück N, Ditschkowski M, et al. Humoral and cellular vaccination responses against SARS-CoV-2 in hematopoietic stem cell transplant recipients. Vaccines (Basel). 2021;9:1075.
pubmed: 34696183
doi: 10.3390/vaccines9101075
Ram R, Hagin D, Kikozashvilli N, Freund T, Amit O, Bar-On Y, et al. Safety and immunogenicity of the BNT162b2 mRNA COVID-19 vaccine in patients after allogeneic HCT or CD19-based CART therapy-a single-center prospective cohort study. Transplant Cell Ther. 2021;27:788–94.
pubmed: 34214738
pmcid: 8242200
doi: 10.1016/j.jtct.2021.06.024
Jiménez M, Roldán E, Fernández-Naval C, Villacampa G, Martinez-Gallo M, Medina-Gil D, et al. Cellular and humoral immunogenicity of the mRNA-1273 SARS-CoV-2 vaccine in patients with hematologic malignancies. Blood Adv. 2022;6:774–84.
pubmed: 34844263
pmcid: 8632354
doi: 10.1182/bloodadvances.2021006101
Clémenceau B, Guillaume T, Coste-Burel M, Peterlin P, Garnier A, Le Bourgeois A, et al. SARS-CoV-2 T-cell responses in allogeneic hematopoietic stem cell recipients following two doses of BNT162b2 mRNA vaccine. Vaccines (Basel). 2022;10:448.
pubmed: 35335079
doi: 10.3390/vaccines10030448
Thümmler L, Koldehoff M, Fisenkci N, Brochhagen L, Horn PA, Krawczyk A, et al. Cellular and humoral immunity after the third vaccination against SARS-CoV-2 in hematopoietic stem-cell transplant recipients. Vaccines (Basel). 2022;10:972.
pubmed: 35746580
doi: 10.3390/vaccines10060972
Gavriilaki E, Papadopoulou A, Touloumenidou T, Stavridou F, Koravou EE, Giannaki M, et al. Neutralizing antibody and T cell responses to SARS-CoV-2 vaccination in hematopoietic cell transplant recipients. Bone Marrow Transplant. 2022;57:1183–6.
pubmed: 35449455
pmcid: 9022618
doi: 10.1038/s41409-022-01675-w
Cuffel A, Maylin S, Le Buanec H, Delaugerre C, Minier M, Bergerat D, et al. Humoral and cellular responses to SARS-CoV-2 BNT162b2 vaccination in allogeneic hematopoietic stem cell transplantation recipients. Vaccine. 2022;40:4682–5.
pubmed: 35840470
pmcid: 9271460
doi: 10.1016/j.vaccine.2022.07.006
Malard F, Gaugler B, Gozlan J, Bouquet L, Fofana D, Siblany L, et al. Weak immunogenicity of SARS-CoV-2 vaccine in patients with hematologic malignancies. Blood Cancer J. 2021;11:142.
pubmed: 34376633
pmcid: 8353615
doi: 10.1038/s41408-021-00534-z
Murray SM, Barbanti M, Campbell C, Brown A, Chen L, Dhanapal J, et al. Impaired humoral and cellular response to primary COVID-19 vaccination in patients less than 2 years after allogeneic bone marrow transplant. Br J Haematol. 2022;198:668–79.
pubmed: 35655410
doi: 10.1111/bjh.18312
Clémenceau B, Le Bourgeois A, Guillaume T, Coste-Burel M, Peterlin P, Garnier A, et al. Strong SARS-CoV-2 T-cell responses after one or two COVID-19 vaccine boosters in allogeneic hematopoietic stem cell recipients. Cells. 2022;11:3010.
pubmed: 36230971
pmcid: 9563037
doi: 10.3390/cells11193010
Meyer T, Ihorst G, Bartsch I, Zeiser R, Wäsch R, Bertz H, et al. Cellular and humoral SARS-CoV-2 vaccination responses in 192 adult recipients of allogeneic hematopoietic cell transplantation. Vaccines (Basel). 2022;10:1782.
pubmed: 36366291
doi: 10.3390/vaccines10111782
Zuo J, Dowell AC, Pearce H, Verma K, Long HM, Begum J, et al. Robust SARS-CoV-2-specific T cell immunity is maintained at 6 months following primary infection. Nat Immunol. 2021;22:620–6.
pubmed: 33674800
pmcid: 7610739
doi: 10.1038/s41590-021-00902-8
Almendro-Vázquez P, Laguna-Goya R, Ruiz-Ruigomez M, Utrero-Rico A, Lalueza A, Maestro de la Calle G, et al. Longitudinal dynamics of SARS-CoV-2-specific cellular and humoral immunity after natural infection or BNT162b2 vaccination. PLoS Pathog. 2021;17: e1010211.
pubmed: 34962970
pmcid: 8757952
doi: 10.1371/journal.ppat.1010211
Adachi E, Nagai E, Saito M, Isobe M, Konuma T, Koga M, et al. Anti-spike protein antibody titer at the time of breakthrough infection of SARS-CoV-2 omicron. J Infect Chemother. 2022;28:1015–7.
pubmed: 35397976
pmcid: 8971116
doi: 10.1016/j.jiac.2022.03.021
Cook LB, O’Dell G, Vourvou E, Palanicawandar R, Marks S, Milojkovic D, et al. Third primary SARS-CoV-2 mRNA vaccines enhance antibody responses in most patients with haematological malignancies. Nat Commun. 2022;13:6922.
pubmed: 36376307
pmcid: 9662771
doi: 10.1038/s41467-022-34657-z
Gilbert PB, Montefiori DC, McDermott AB, Fong Y, Benkeser D, Deng W, et al. Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. Science. 2022;375:43–50.
pubmed: 34812653
doi: 10.1126/science.abm3425
Schwarzkopf S, Krawczyk A, Knop D, Klump H, Heinold A, Heinemann FM, et al. Cellular immunity in COVID-19 convalescents with PCR-confirmed infection but with undetectable SARS-CoV-2-specific IgG. Emerg Infect Dis. 2021;27:122–9.
pmcid: 7774536
doi: 10.3201/eid2701.203772
Yi JS, Rosa-Bray M, Staats J, Zakroysky P, Chan C, Russo MA, et al. Establishment of normative ranges of the healthy human immune system with comprehensive polychromatic flow cytometry profiling. PLoS ONE. 2019;14: e0225512.
pubmed: 31825961
pmcid: 6905525
doi: 10.1371/journal.pone.0225512
Widge AT, Rouphael NG, Jackson LA, Anderson EJ, Roberts PC, Makhene M, et al. Durability of responses after SARS-CoV-2 mRNA-1273 vaccination. N Engl J Med. 2021;384:80–2.
pubmed: 33270381
doi: 10.1056/NEJMc2032195
Shrotri M, Navaratnam AMD, Nguyen V, Byrne T, Geismar C, Fragaszy E, et al. Spike-antibody waning after second dose of BNT162b2 or ChAdOx1. Lancet. 2021;398:385–7.
pubmed: 34274038
pmcid: 8285117
doi: 10.1016/S0140-6736(21)01642-1
Levin EG, Lustig Y, Cohen C, Fluss R, Indenbaum V, Amit S, et al. Waning immune humoral response to BNT162b2 Covid-19 vaccine over 6 months. N Engl J Med. 2021;385: e84.
pubmed: 34614326
doi: 10.1056/NEJMoa2114583
Ibarrondo FJ, Fulcher JA, Goodman-Meza D, Elliott J, Hofmann C, Hausner MA, et al. Rapid decay of anti-SARS-CoV-2 antibodies in persons with mild Covid-19. N Engl J Med. 2020;383:1085–7.
pubmed: 32706954
doi: 10.1056/NEJMc2025179
Long QX, Tang XJ, Shi QL, Li Q, Deng HJ, Yuan J, et al. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat Med. 2020;26:1200–4.
pubmed: 32555424
doi: 10.1038/s41591-020-0965-6
Leclerc M, Redjoul R, Le Bouter A, Beckerich F, Robin C, Parinet V, et al. Determinants of SARS-CoV-2 waning immunity in allogeneic hematopoietic stem cell transplant recipients. J Hematol Oncol. 2022;15:27.
pubmed: 35303906
pmcid: 8931584
doi: 10.1186/s13045-022-01250-2
Piñana JL, Martino R, Vazquez L, López-Corral L, Pérez A, Chorão P, et al. SARS-CoV-2-reactive antibody waning, booster effect and breakthrough SARS-CoV-2 infection in hematopoietic stem cell transplant and cell therapy recipients at one year after vaccination. Bone Marrow Transplant. 2023;58:567–80.
pubmed: 36854892
pmcid: 9974060
doi: 10.1038/s41409-023-01946-0
Laurén I, Havervall S, Ng H, Lord M, Pettke A, Greilert-Norin N, et al. Long-term SARS-CoV-2-specific and cross-reactive cellular immune responses correlate with humoral responses, disease severity, and symptomatology. Immun Inflamm Dis. 2022;10: e595.
pubmed: 35349756
pmcid: 8962644
doi: 10.1002/iid3.595
Rydyznski Moderbacher C, Ramirez SI, Dan JM, Grifoni A, Hastie KM, Weiskopf D, et al. Antigen-specific adaptive immunity to SARS-CoV-2 in acute COVID-19 and associations with age and disease severity. Cell. 2020;183:996–1012.
pubmed: 33010815
pmcid: 7494270
doi: 10.1016/j.cell.2020.09.038
Mathew D, Giles JR, Baxter AE, Oldridge DA, Greenplate AR, Wu JE, et al. Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications. Science. 2020;369: eabc8511.
pubmed: 32669297
pmcid: 7402624
doi: 10.1126/science.abc8511
Turner JS, Kim W, Kalaidina E, Goss CW, Rauseo AM, Schmitz AJ, et al. SARS-CoV-2 infection induces long-lived bone marrow plasma cells in humans. Nature. 2021;595:421–5.
pubmed: 34030176
doi: 10.1038/s41586-021-03647-4
Millington KA, Innes JA, Hackforth S, Hinks TS, Deeks JJ, Dosanjh DP, et al. Dynamic relationship between IFN-gamma and IL-2 profile of Mycobacterium tuberculosis-specific T cells and antigen load. J Immunol. 2007;178:5217–26.
pubmed: 17404305
doi: 10.4049/jimmunol.178.8.5217
Kundu R, Narean JS, Wang L, Fenn J, Pillay T, Fernandez ND, et al. Cross-reactive memory T cells associate with protection against SARS-CoV-2 infection in COVID-19 contacts. Nat Commun. 2022;13:80.
pubmed: 35013199
pmcid: 8748880
doi: 10.1038/s41467-021-27674-x
Poon MML, Rybkina K, Kato Y, Kubota M, Matsumoto R, Bloom NI, et al. SARS-CoV-2 infection generates tissue-localized immunological memory in humans. Sci Immunol. 2021;6: eabl9105.
pubmed: 34618554
pmcid: 8626868
doi: 10.1126/sciimmunol.abl9105
Roukens AHE, Pothast CR, König M, Huisman W, Dalebout T, Tak T, et al. Prolonged activation of nasal immune cell populations and development of tissue-resident SARS-CoV-2-specific CD8+ T cell responses following COVID-19. Nat Immunol. 2022;23:23–32.
pubmed: 34937933
doi: 10.1038/s41590-021-01095-w
Isho B, Abe KT, Zuo M, Jamal AJ, Rathod B, Wang JH, et al. Persistence of serum and saliva antibody responses to SARS-CoV-2 spike antigens in COVID-19 patients. Sci Immunol. 2020;5: eabe5511.
pubmed: 33033173
pmcid: 8050884
doi: 10.1126/sciimmunol.abe5511
Wang Z, Lorenzi JCC, Muecksch F, Finkin S, Viant C, Gaebler C, et al. Enhanced SARS-CoV-2 neutralization by dimeric IgA. Sci Transl Med. 2021;13: eabf1555.
pubmed: 33288661
doi: 10.1126/scitranslmed.abf1555
Molodtsov IA, Kegeles E, Mitin AN, Mityaeva O, Musatova OE, Panova AE, et al. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific T cells and antibodies in coronavirus disease 2019 (COVID-19) protection: a prospective study. Clin Infect Dis. 2022;75:e1–9.
pubmed: 35435222
pmcid: 9047235
doi: 10.1093/cid/ciac278
Goel RR, Painter MM, Apostolidis SA, Mathew D, Meng W, Rosenfeld AM, et al. mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern. Science. 2021;374: abm0829.
pubmed: 34648302
pmcid: 9284784
doi: 10.1126/science.abm0829
Tarke A, Coelho CH, Zhang Z, Dan JM, Yu ED, Methot N, et al. SARS-CoV-2 vaccination induces immunological T cell memory able to cross-recognize variants from Alpha to Omicron. Cell. 2022;185:847–59.
pubmed: 35139340
pmcid: 8784649
doi: 10.1016/j.cell.2022.01.015